New approaches to pharmacogenetics of drug-induced hyperprolactinemia in patients with schizophrenia

The pathogenesis of the development of drug-induced disorders while taking antipsychotic drugs is not well understood. The aim of the work is to study polymorphic variants of the multidrug resistance protein gene and genes encoding the metabolism and synthesis of dopamine and serotonin enzymes in an...

Full description

Saved in:
Bibliographic Details
Published inObozrenie psikhiatrii i medit︠s︡inskoĭ psikhologii imeni V.M. Bekhtereva no. 4-1; pp. 21 - 23
Main Author Ivanova, S. A.
Format Journal Article
LanguageEnglish
Russian
Published Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation 09.12.2019
Subjects
schizophrenia, antipsychotic-induced hyperprolactinemia, gene polymorphisms, pharmacogenetics
Online AccessGet full text

Cover

More Information
Summary:The pathogenesis of the development of drug-induced disorders while taking antipsychotic drugs is not well understood. The aim of the work is to study polymorphic variants of the multidrug resistance protein gene and genes encoding the metabolism and synthesis of dopamine and serotonin enzymes in antipsychotic-induced hyperprolactinemia in schizophrenia patients. As a result of a comprehensive study of 446 patients with schizophrenia and genotyping of 25 polymorphic variants of the MDR1, COMT, MAO-A, MAO-B, TPH1 and TPH2 genes, associations of polymorphisms rs1045642, rs2032582, rs4148739 (MDR1), rs6323 (MAO-А), rs1799836 (MAO-B) were revealed with the development of hyperprolactinemia. Further research is needed to develop personalized approaches to therapy.
ISSN:2313-7053
2713-055X
DOI:10.31363/2313-7053-2019-4-1-21-23